Company news

Bicara Therapeutics Inc. news in 2026

Bicara Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.

View company

Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

November 9, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

November 4, 2026

Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8: 30 AM ET

November 2, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 5, 2026

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

August 11, 2026

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8: 30 AM ET

August 4, 2026

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

July 28, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

May 13, 2026

Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 11, 2026

Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8: 30 AM ET

May 4, 2026

Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 29, 2026

Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8: 30 AM ET

March 22, 2026

Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

March 4, 2026

Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 26, 2026

Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants

February 24, 2026

Bicara Therapeutics Announces Proposed Public Offering of Common Stock

February 24, 2026

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

February 18, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 5, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

February 4, 2026

Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook

January 11, 2026

Calls in 2026

Decks in 2026